Daniella Beckman

Former Chief Financial Officer

Board Member

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year	Company	Role	Salary	Bonus	Stock awards	Option awards	Incentive	Other	Total
2025	Tango Therapeutics, Inc. (TNGX)	Former Chief Financial Officer	$502,877	—	$76,006	$314,617	$244,117	$18,158	$1,155,775
2024	Tango Therapeutics, Inc. (TNGX)	Chief Financial Officer	$486,314	—	$483,992	$1,964,682	$213,492	$17,810	$3,166,290
2023	Tango Therapeutics, Inc. (TNGX)	Chief Financial Officer	$441,777	—	$170,778	$691,570	$209,999	$8,620	$1,522,744
2022	Tango Therapeutics, Inc. (TNGX)	Chief Financial Officer	$425,100	—	—	$897,750	$191,614	$2,415	$1,516,879
2021	Tango Therapeutics, Inc. (TNGX)	Chief Financial Officer	$377,945	—	—	$2,630,841	$164,562	$3,317	$3,176,664
2020	Tango Therapeutics, Inc. (TNGX)	Chief Financial Officer	$323,447	—	—	$368,323	$131,828	$10,776	$834,374

Executive changes

Terminated principal accounting officer at Tango Therapeutics, Inc. (TNGX)
2026-04-15
Terminated Chief Financial Officer, principal accounting officer and principal financial officer at Tango Therapeutics, Inc. (TNGX)
2026-04-15

Earnings-call appearances

No earnings-call appearances recorded yet.